ME/CFS Evidence Browser — Classified Studies on Myalgic Encephalomyelitis

41–60 of 381 studies

E1 ReplicatedPEM unclearModerate confidenceRCTEditor reviewed

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.

Young, Joel L, Powell, Richard N, Powell, Anna et al.·Journal of psychopharmacology (Oxford, England)·2025

Researchers tested whether a medication called solriamfetol could help reduce fatigue in people with ME/CFS. In this 8-week study, some patients received the medication (starting at 75mg and potentially increasing to 150mg) while others received a placebo. By week 8, patients taking solriamfetol reported significantly less severe fatigue compared to those on placebo, and they also showed improvements in thinking and memory abilities. The medication was generally well tolerated, though some people experienced sleep problems and headaches.

Evidence Atlas

Evidence browser

Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment.

Relationships between fatigue, cognitive function, and upright activity in a randomized trial of oxaloacetate for myalgic encephalomyelitis/chronic fatigue syndrome.

Yeast Beta-Glucan Supplementation with Multivitamins Attenuates Cognitive Impairments in Individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial.

A prospective randomized, double-blind placebo-controlled study to evaluate the effectiveness of neuroprotective therapy using functional brain MRI in patients with post-covid chronic fatigue syndrome.

Cerebral blood flow is reduced in ME/CFS during head-up tilt testing even in the absence of hypotension or tachycardia

Kinesiophobia and maladaptive coping strategies prevent improvements in pain catastrophizing following pain neuroscience education in fibromyalgia/chronic fatigue syndrome: An explorative study.

Does neuropsychological test performance predict outcome of cognitive behavior therapy for Chronic Fatigue Syndrome and what is the role of underperformance?

Use of lisdexamfetamine dimesylate in treatment of executive functioning deficits and chronic fatigue syndrome: a double blind, placebo-controlled study.

Homeopathy for mental fatigue: lessons from a randomized, triple blind, placebo-controlled cross-over clinical trial.

The effect of cognitive behaviour therapy for chronic fatigue syndrome on self-reported cognitive impairments and neuropsychological test performance.

Does methylphenidate reduce the symptoms of chronic fatigue syndrome?

Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome.

Exploratory open label, randomized study of acetyl- and propionylcarnitine in chronic fatigue syndrome.

Examining the influence of biological and psychological factors on cognitive performance in chronic fatigue syndrome: a randomized, double-blind, placebo-controlled, crossover study.

Neuropsychological performance and noradrenaline function in chronic fatigue syndrome under conditions of high arousal.

An assessment of cognitive function and mood in chronic fatigue syndrome.

Disentangling comorbidity: symptom dimensions of internalizing and functional disorders in a large general population sample.

Assessment of dynamic cerebral blood flow changes during cognitive tasks in patients with post-COVID-19 syndrome.

Validation of the Wood Mental Fatigue Inventory in adolescents with myalgic encephalomyelitis/chronic fatigue syndrome.

Two neurocognitive domains identified for patients with myalgic encephalomyelitis/chronic fatigue syndrome and post-acute sequelae of COVID-19.

Curated Collections

Neuroinflammation Evidence

Metabolism & Mitochondria

Biomarkers

PEM-Specific Research